WeVote
Log In

Bill

Bill

LD 627

An Act To Require Insurance Coverage For Glucagon-Like Peptide-1 Receptor Agonist Medication

132nd Legislature (2025-2026) Introduced by Dan Ankeles and 8 co-sponsors

Mandates health insurance coverage for GLP-1 receptor agonist medications, expanding access for obesity and type 2 diabetes patients.

Pursuant to Joint Rule 310.3 Placed in Legislative Files (DEAD)
#healthinsurance #insurance #weightlossmedications
0
WeVote Research Nonpartisan
Bill Summary · LD 627

Summary of LD 627: An Act To Require Insurance Coverage For Glucagon-Like Peptide-1 Receptor Agonist Medication

Overview

LD 627 proposes that health insurance plans provide coverage for glucagon-like peptide-1 (GLP-1) receptor agonist medications. These drugs are commonly used to treat obesity/weight management and type 2 diabetes. The bill’s aim is to require insurance coverage for these medications under health plans.

Purpose and intent

  • Ensure insurance coverage for GLP-1 receptor agonist medications as part of health insurance plans.
  • Increase access to these medications for eligible patients by reducing potential barriers created by lack of coverage or high out-of-pocket costs.

Key provisions (as indicated by the bill’s title and status)

  • Mandate that health insurance plans cover GLP-1 receptor agonist medications.
  • The specific scope, exemptions, formulary rules, patient cost-sharing limits, prior authorization standards, and any phase-in timelines are not provided in the available summary. (No bill text is included here.)

Affected parties

  • Insured individuals who may benefit from GLP-1 receptor agonist therapies (including those managing obesity/weight loss and type 2 diabetes).
  • Health insurers and payer systems that administer or provide coverage for prescription medications.
  • Employers and plan sponsors offering group health plans that include coverage for prescription drugs.

Procedural history and status

  • Introduced: February 20, 2025.
  • Referred to: Committee on Health Coverage, Insurance and Financial Services (pursuant to Joint Rule 308.2).
  • 2025-02-20: Bill received by the Clerk of the House and ordered printed.
  • 2025-03-26: Work session held; bill voted ONTP (Ought Not To Pass).
  • 2025-04-01: Reported Out - ONTP.
  • 2025-04-08: Pursuant to Joint Rule 310.3, placed in Legislative Files (DEAD) — effectively ending the bill’s consideration for the current session.
  • Carried over on 2025-03-21 to the next special or regular session of the 132nd Legislature, but ultimately designated DEAD in the legislative files.

Potential impact (contextual)

  • If enacted, could improve patient access to GLP-1 therapies by ensuring coverage, potentially reducing out-of-pocket costs for eligible patients.
  • May increase short-term costs for insurers or plan sponsors and influence formulary design and negotiation with manufacturers.
  • Could affect utilization patterns of GLP-1 medications for obesity and diabetes management, with potential downstream effects on health outcomes and long-term costs.

Note

As of the latest actions, LD 627 is dead for the current session. If interest remains, the bill could be reintroduced in a future session with revised language or different endorsements.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.